Media Release
From: Melanoma Institute AustraliaEMBARGO: 06:00, 22 JULY 2019 AEST
Breast cancer drug may hold key to tackling most deadly type of melanoma
An Australian-led international team of researchers has discovered that a drug traditionally used to treat a type of breast cancer may hold the key to treating an aggressive and deadly form of melanoma.
Mucosal melanoma, which occurs on the inner surfaces of the body such as the mouth, nose and anogenital region and
The international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has uncovered the diverse genetic drivers for mucosal melanoma
Melanoma Institute Australia Co-Medical Director and study lead author, Professor Richard Scolyer, says the study allowed researchers to not only look for new drug targets, but
“We now understand the genetic drivers of mucosal
“The ramifications of this study are immense and are critical in us reaching our goal of zero deaths from melanoma.”
Published online at Nature Communications, the study detailed the genetic analysis of 67 mucosal melanoma tumours from patients from Australia, China, the United States and Europe. Using both whole-genome sequencing and whole-
“While advancements in treatment have drastically improved survival outcomes for cutaneous (or skin) melanoma patients, those treatments do not work as well for mucosal melanoma patients,” Professor Scolyer added.
“But now we can build our treatment arsenal for this group of patients
The study also found
While rare in Western populations like in Australia, where it makes up less than 2% of all melanoma cases, mucosal melanoma makes up a third
A previous study also coming from the Australian Melanoma Genome Project found that mucosal melanoma
There are no known risk factors for mucosal melanoma, making prevention strategies difficult. It
“The next exciting step is for Melanoma Institute Australia to develop a clinical trial to test classes of drugs and their effectiveness for treating mucosal melanoma,” Melanoma Institute Australia Co-Medical Director and study author Professor Georgina Long said.
“This is the new frontier in melanoma treatment, with very real benefits for patients internationally, and we are proud to be leading the world in saving lives.”
ENDS
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Nature Communications